يعرض 421 - 440 نتائج من 14,107 نتيجة بحث عن '(( significant decrease decrease ) OR ( ((significant a) OR (significant i)) decrease ))~', وقت الاستعلام: 0.87s تنقيح النتائج
  1. 421

    S1 File - حسب Qingqing Hao (5464070)

    منشور في 2024
    "…Compared with HF group, after CCM intervention, the expression of Beclin1 and LC3B proteins decreased, while the P62 protein increased, and the LC3B(II/I) ratio decreased (P<0.05). 2) The expression of Bcl-2, ALDH2 protein and Bcl-2 mRNA decreased compared with the Sham group (P<0.05), while the expression of Bax, Caspase-3 protein and mRNA was significantly increased (P<0.05). …"
  2. 422

    The mean and standard deviation of parameters. حسب Sadaf Sepasgozar Sarkhosh (20436143)

    منشور في 2024
    "…Additionally, one-way ANCOVA revealed a significant difference between the groups post-treatment (F(1,31) = 6.011, P = 0.020, η2 = 0.162) and one month post-treatment (F(1,31) = 4.889, P = 0.035, η2 = 0.136), with ML SI being significantly lower in the exergaming group than the balance training group at both time points. …"
  3. 423

    The ANCOVA and Post_hoc results. حسب Sadaf Sepasgozar Sarkhosh (20436143)

    منشور في 2024
    "…Additionally, one-way ANCOVA revealed a significant difference between the groups post-treatment (F(1,31) = 6.011, P = 0.020, η2 = 0.162) and one month post-treatment (F(1,31) = 4.889, P = 0.035, η2 = 0.136), with ML SI being significantly lower in the exergaming group than the balance training group at both time points. …"
  4. 424

    CONSORT flowchart. حسب Sadaf Sepasgozar Sarkhosh (20436143)

    منشور في 2024
    "…Additionally, one-way ANCOVA revealed a significant difference between the groups post-treatment (F(1,31) = 6.011, P = 0.020, η2 = 0.162) and one month post-treatment (F(1,31) = 4.889, P = 0.035, η2 = 0.136), with ML SI being significantly lower in the exergaming group than the balance training group at both time points. …"
  5. 425

    Time to stabilization in the vertical direction. حسب Sadaf Sepasgozar Sarkhosh (20436143)

    منشور في 2024
    "…Additionally, one-way ANCOVA revealed a significant difference between the groups post-treatment (F(1,31) = 6.011, P = 0.020, η2 = 0.162) and one month post-treatment (F(1,31) = 4.889, P = 0.035, η2 = 0.136), with ML SI being significantly lower in the exergaming group than the balance training group at both time points. …"
  6. 426

    The description of games. حسب Sadaf Sepasgozar Sarkhosh (20436143)

    منشور في 2024
    "…Additionally, one-way ANCOVA revealed a significant difference between the groups post-treatment (F(1,31) = 6.011, P = 0.020, η2 = 0.162) and one month post-treatment (F(1,31) = 4.889, P = 0.035, η2 = 0.136), with ML SI being significantly lower in the exergaming group than the balance training group at both time points. …"
  7. 427

    The description of balance training. حسب Sadaf Sepasgozar Sarkhosh (20436143)

    منشور في 2024
    "…Additionally, one-way ANCOVA revealed a significant difference between the groups post-treatment (F(1,31) = 6.011, P = 0.020, η2 = 0.162) and one month post-treatment (F(1,31) = 4.889, P = 0.035, η2 = 0.136), with ML SI being significantly lower in the exergaming group than the balance training group at both time points. …"
  8. 428
  9. 429
  10. 430
  11. 431
  12. 432
  13. 433
  14. 434
  15. 435
  16. 436
  17. 437
  18. 438
  19. 439
  20. 440

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"